Robert Hawkins
Chief Tech/Sci/R&D Officer presso INSTIL BIO, INC.
Patrimonio netto: 31 977 $ in data 31/03/2024
Profilo
Robert Edward Hawkins is the founder of Instil Bio (UK) Ltd.
He currently holds the position of Head-Research & Development at Instil Bio, Inc. and Independent Non-Executive Director at BiVictriX Therapeutics Plc.
In the past, he served as a Director at Instil Bio, Inc. and as an Independent Non-Executive Director at Motif Bio Plc.
He was also an Honorary Professor at The University of Manchester.
Hawkins received his undergraduate and doctorate degrees from the University of Cambridge and his doctorate degree from University College London.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 31/12/2022 | 225 000 ( 0.27% ) | 31 977 $ | 31/03/2024 |
Posizioni attive di Robert Hawkins
| Società | Posizione | Inizio |
|---|---|---|
| BIVICTRIX THERAPEUTICS PLC | Director/Board Member | 22/09/2021 |
| INSTIL BIO, INC. | Chief Tech/Sci/R&D Officer | 11/11/2022 |
Precedenti posizioni note di Robert Hawkins
| Società | Posizione | Fine |
|---|---|---|
| INSTIL BIO, INC. | Director/Board Member | 01/07/2020 |
| Instil Bio (UK) Ltd. | Chief Executive Officer | 01/01/2020 |
| The University of Manchester | Corporate Officer/Principal | - |
| MOTIF BIO PLC | Director/Board Member | - |
Formazione di Robert Hawkins
| University of Cambridge | Doctorate Degree |
| University College London | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BIVICTRIX THERAPEUTICS PLC | Health Technology |
| INSTIL BIO, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
| Instil Bio (UK) Ltd. | |
Motif Bio Plc
 Motif Bio Plc Pharmaceuticals: MajorHealth Technology Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ. | Health Technology |
- Borsa valori
- Insiders
- Robert Hawkins
